# A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma

> **NCT02659020** · PHASE1,PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 310 (actual)

## Conditions studied

- Soft Tissue Sarcoma

## Interventions

- **DRUG:** Olaratumab
- **DRUG:** Gemcitabine
- **DRUG:** Docetaxel
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02659020
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-01
- **Primary completion:** 2020-07-28
- **Final completion:** 2021-04-27
- **Target enrollment:** 310 (ACTUAL)
- **Last updated:** 2022-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02659020

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02659020, "A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02659020. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*